NOVARTIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.85 CHF | -0.18% |
|
-1.49% | -0.02% |
| Apr. 17 | Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years | MT |
| Apr. 17 | Novartis: positive efficacy data in MS | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
93.02
USD
Average target price
106.9
USD
Spread / Average Target
+14.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.02% | 204B | |
| +28.79% | 673B | |
| +24.81% | 551B | |
| -7.64% | 348B | |
| +15.00% | 317B | |
| +5.99% | 288B | |
| +2.47% | 210B | |
| -9.98% | 195B | |
| -11.71% | 145B | |
| -8.32% | 142B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis' Phase 3 Lung Cancer Drug Trial Fails to Meet Primary Endpoint; Shares Down Pre-Bell
